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MUSC-MC Formulary System:
What Every Practitioner Needs to Know
The formulary system is a process whereby the professional
staff, working through the Pharmacy and Therapeutics Committee, evaluates, appraises, and selects medications that are considered to be most useful in patient care. The formulary system
is an important mechanism for
optimizing patient outcomes
while controlling expenditures
(see Policy C-82).
The MUSC-MC Formulary of
Accepted Drugs is a list of approved medications and dosage
forms available for use throughout the Medical Center. The formulary is a tool that helps practitioners make rational drug therapy decisions. After careful review of current medical literature, the Pharmacy and Therapeutics Committee determines
which agents are added to and
deleted from the formulary.
The formulary is accessible
online at the Formulary and
Drug Information Resources
web page. A link can be found
on the MUSC-MC Intranet or at
www.formularyproductions.com/musc.
The online formulary contains
medications and respective formulations that are approved for

use, comments regarding restrictions, links to medication-specific
preprinted order forms, and links
to the MICROMEDEX® monograph, patient education leaflet,
and PubMed citations for each
medication. Other items pertinent
to the formulary are available
online including the following:
links to medication use guidelines,
charts, and policies; useful Internet sites for health care practitioners; and pharmacy news stories.
Any physician may prescribe unrestricted formulary medications
listed in the MUSC-MC Formulary of Accepted Drugs. Nurse
practitioners and physician assistants may prescribe formulary
medications based on their scope
of practice in accordance with
South Carolina law and based on
the individual collaborative practice agreement that each clinician
has with their supervising physician.
The Pharmacy and Therapeutics
Committee restricts the use of certain medications on the formulary.
The purpose is to ensure patient
safety and appropriate utilization.
Medications may be restricted by
physician status, physician specialty, specific patient care unit,
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specific disease state, or specific
patient population. Physicians
may prescribe formulary restricted
medications so long as the condition of the formulary restriction is
met. Nurse practitioners and physician assistants may prescribe
formulary restricted medications
within the scope of their practice
and based on the individual collaborative practice agreement, so
long as the condition of the formulary restriction is met.
Restricted medications cannot be
ordered outside of the restriction
unless approval is obtained by the
Chair of the Pharmacy and Therapeutics Committee. Only attending physicians may request approval. Formulary restrictions are
noted in the online formulary and
in the pharmacy order entry system under each specific medication. Additionally, a cumulative
list of restricted medications is
available on the front page of the
online formulary.
Authority to dispense most formulary medications is delegated to
the pharmacist by the Director of
Pharmacy Services. However, the

Pharmacy and Therapeutics
Committee requires that prior to
dispensing high-cost formulary
medications, a second-level administrative approval must be
obtained. A high-cost formulary
medication is defined as one in
which the acquisition cost for the
expected course of therapy exceeds $5000. If the acquisition
cost for the expected course is
$5000 or greater, the pharmacist
processing the order will contact
the Director of Pharmacy Services or the Chair of the Pharmacy and Therapeutics Committee to obtain second-level administrative approval prior to
processing the order.
Attending-level members of the
medical or dental faculty may
request that a medication or dosage form be added to or deleted
from the formulary or that a
change be made in a current restrictions. Formulary request
forms may be obtained from the
Drug Information Center at extension 2-3896, by e-mail
(druginfo@musc.edu), or online
on the formulary web site. The
link to the form is located above

the search area. The completed
form must be countersigned by the
appropriate department chair or
division chief. Once a request is
received, a review is prepared by
the Drug Information Center staff
for presentation to the Pharmacy
and Therapeutics Committee. Reviews are based on published
medical literature and focus on the
efficacy, safety, tolerability, and
economic impact of the agent.
Actions taken by the Pharmacy
and Therapeutics Committee are
generally given an effective date
on or about the 15th day of the following month.
Any action
deemed necessary for patient
safety becomes effective immediately.
Following each meeting, requesters are notified in writing of the
Committee’s actions. Changes to
the formulary are published each
month in Pharmacy and Therapeutics Update.
Questions regarding the formulary
should be referred to the Drug Information Center at 2-3896 or
druginfo@musc.edu.

Clinical Pharmacy On-call Services
The Department of Pharmacy Services provides continuous 24-hour
clinical pharmacy coverage. On
weekdays, please consult the pharmacist covering your service. For
nighttime, weekend, and holiday
coverage, please page the clinical
pharmacist on-call.
If you require clinical pharmacy
services and are on a service or
unit that does not have regular
clinical pharmacy coverage,

please page the clinical pharmacist on-call or call the Drug
Information Center at extension
2-3896. The clinical pharmacist
on-call can provide the following services:
▪ design and monitor a patient’s
▪
▪
▪
▪

pharmacotherapy regimen
provide pharmacokinetic consults
provide intensive patient counseling
provide guidance for initiating or
adjusting parenteral or enteral
nutrition
follow up on adverse drug events

Clinical pharmacy on-call services
are available for adult, pediatric,
psychiatric, and inpatient family
medicine services, as well as managing direct thrombin inhibitors
(per pharmacy-to-dose protocol) .
To contact a pharmacist on-call,
go to http://simonweb.musc.edu
and search “pharmacy” using the
on-call search feature or call the
paging operator at 2-2123 and ask
for the specific oncall service that
is needed.
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Prescribing Nonformulary Medications
Nonformulary status applies to any medication, brand name, or dosage form that is not listed in the MUSC-MC
Formulary of Accepted Drugs. Nonformulary medications are not routinely stocked in the pharmacy but will
be obtained and dispensed with appropriate approval. Medical staff, house staff, nurse practitioners and physician assistants (subject to licensure requirements or other legal limitations and with delineated clinical privileges) are authorized to prescribe nonformulary medications.
To facilitate the approval process, prescribers must provide clinical justification for the use of a nonformulary
medication on the physician’s order sheet. Possible clinical justifications include:
▪ newly marketed medication that has not been considered for formulary addition,
▪ patient has experienced an adverse reaction to all formulary alternatives, and these reactions have been
documented (prescriber to specify medication and reaction),
▪ patient has experienced therapeutic failure to all formulary alternatives,
− prescriber to specify medication(s) used
▪ patient stabilized on a specific medication prior to admission, or
▪ nonformulary medication was specifically recommended by a consulting service.
Pharmacists are authorized to dispense nonformulary medication when clinically justified. The pharmacist
will contact the physician when clinical justification for using a nonformulary medication is deemed inappropriate or is not indicated on the physician’s order sheet.

Generic Medication Pricing Program
By: Heather Kokko, PharmD
Manager, Ambulatory Pharmacy Services
MUSC Ambulatory Pharmacies now offer a Generic Medication Pricing Program for selected generic medications. The selected generics can be found on the MUSC website at the following link:
http://www.musc.edu/pharmacyservices/Ambulatory%20Svc/GenMedPricing.pdf.

The Department of Pharmacy Services is pleased to offer these special prices for all patients and employees
who get their prescriptions filled at any of the MUSC Pharmacies. A 30-day supply of the selected generic
medications is $4 and a 90-day supply is $10. Additionally, a number of contraceptives will be available at
special pricing. The pharmacists can transfer prescriptions for any eligible patient. Please let your patients
and colleagues know about this new program. Call Heather Kokko at 792-1009 for any questions.
Ashley River Tower Pharmacy
Located on 1Upper in ART
Monday through Friday
8:30 AM to 5:30 PM
(843) 876-5585

Rutledge Tower Pharmacy
Located on the 1st floor of Rutledge Tower
Monday through Friday
Saturday
8:30 AM to 5:30 PM
9:00 AM to 1:00 PM
(843) 792-7233

Hollings Cancer Center Pharmacy
Located on the 2nd floor of HCC
Monday through Friday
9:00 AM to 5:00 PM
(843) 792-6440

University Hospital Pharmacy
Located on the 1st floor of University Hospital
Monday through Friday
8:30 AM to 6:30 PM
(843) 792-4646
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Online Medication Error and Adverse Drug Reaction Reporting
Practitioners are urged to use the
University HealthSystem Consortium Patient Safety Net to report
potential or actual medication errors or adverse drug reactions
(ADRs).

utes. If more time is needed,
please remember to extend your
time at the top of the screen. If
the time is not reset, the system
will automatically log you off
and all your information will be
lost.

To access the reporting system
click on the UHC PSN desktop icon
located on all LYNX work stations
and follow the menu-driven instructions.
The online form is easy to complete
and should take less than 15 min-

For ADRs include suspect medication(s), dose(s), clinical presentation, description of how the
ADR was managed, and the patient outcome.
All ADRs detected are reported to
the Pharmacy and Therapeutics
Committee for potential followup. If you have any questions
about the ADR system, please
contact the Drug Information Center at extension 2-3896.

Please include all pertinent details related to the occurrence.

Required Elements for Inpatient and Clinic Medication Orders
For a medication order to be considered complete and valid, the Medical Executive Committee has mandated
that the criteria below be met. For more detailed information regarding medication orders, please refer to the
Policy C-78 (Medication Orders) located in the MUSC Medical Center Clinical Policy Manual. The policy
also contains the list of prohibited abbreviations. The link to the guidelines can be found on the online formulary under Medication Safety Resources (www.formularyproductions.com/musc).
Regarding Orders for Adult Patients
Regarding Orders for Pediatric Patients
[< 17 years of age (except for obstetric patients)]
▪ Prohibited abbreviations MUST NOT be used
▪ Prohibited abbreviations MUST NOT be used
▪ Date and time MUST be written (military time)
▪ Weight in kilograms required for medications that are ▪ Date and time MUST be written (military time)
▪ Weight in kilograms or grams on ALL orders
dosed based on weight
− Example: chemotherapy
▪ Medication name
▪ Medication name
− Same as adult order guidelines
− generic name preferred, specify salt form (eg, potassium ▪ Dose
▪

▪
▪
▪

▪

chloride); chemical names for electrolytes are acceptable,
except for MgSO4
Dose and Dosage units
− metric units only; do not use ampules, tablets, or bottles as
the only dosage unit; specify the concentration (eg, mg/mL),
if applicable
Diluent
− specify if requiring diluent other than the standard
(ie, 5% dextrose or 0.9% NaCl)
Route of administration
Frequency or interval
− all inpatient orders for PRN medications must include an
interval and an indication do not use range orders with variable dosing frequencies (eg, q 4 - 6 hours)
− outpatient order MUST include indication for use or ICD9
Signature/credentials; pager number

▪
▪
▪
▪
▪

− dose/kg/interval required for all patients weighing less
than 40 kg (eg, mg/kg/dose or mg/kg/day);
− the dose/kg/interval should be specified for one of the
medications in combination preparations
− elemental preparations (eg, iron, zinc) should be ordered based on the desired dose of the element, not the
salt
Dosage units
− Same as adult order guidelines
Diluent
− Same as adult order guidelines
Route of administration
Frequency or interval
− Same as adult order guidelines
Signature/credentials; pager number
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Accurate Documentation Makes Economic CENT$
By: Kimberly Andrews, PharmD/MBA Candidate
Third party payers such as Medicare and private insurance companies rely on proper documentation
and coding to reimburse clinics
and hospitals for medical services
provided to their beneficiaries. To
determine the correct payment for
services, insurance payers may
require the following billing details:
− drug codes, which are part of the

Healthcare Common Provider Coding System (HCPCS),
− administration codes using Current
Procedural Terminology (CPT),
− diagnosis codes that are developed
from the International Classification of Diseases, 9th edition
(ICD-9).

There are different levels of
HCPCS codes available. Level II
codes refer primarily to identification of medical products, supplies,
and services. These codes are used
by healthcare providers when submitting claims for drugs and other
supplies used in the medical setting. These codes are also referred
to as alphanumeric codes because
they consist of a single letter followed by 4 numeric digits.

CPT codes are used to provide
information about services and
procedures performed in the
medical setting. These codes
also cover the administration of
medications such as intravenous
infusions or chemotherapeutic
agents.
Finally, to explain why the
medications were given and why
the services were provided to a
patient, ICD-9 codes are used.
ICD-9 codes can be used to describe the signs, symptoms, injuries, diseases, and conditions
that a patient may have when
being seen by a healthcare provider. To keep pace with
changes in medical care, new
codes are developed for new
procedures, current codes may
be revised, and old, unused
codes may be discarded.
Submitting the wrong codes can
affect the financial status of the
organization. It could result in
improper payment, delay in payment, or denial of payment. The
hospital and clinics depend on

timely reimbursement payments to
help cover daily operation costs of
the facility. The continuous flow
of cash helps the organization provide necessary resources for staff
and patients including new office
equipment, medical equipment,
personnel, and funds for expansion.
The key to accurate billing is the
ICD-9 code. This code describes
the medical necessity for services,
procedures, and supplies a patient
receives during a visit. Also, for
patients who require prior authorization for services and medications, the ICD-9 code helps to determine approval and must be provided when making the request.
When the diagnosis of the patient
and the service or medication
given does not match, it results in
loss of revenue and reduced or
negative profit margin. See example below.
Changes were recently made to
MUSC Policy C78: Medication
Orders.

− ALL outpatient (emergency services,
observation units, and clinics) medication orders (hand-written,
Patient diagnosed with Chronic Kidney Disease Stage IV receives
pre-printed, or practice partdarbepoetin (Aranesp®) in clinic
ner templates) MUST include the appropriate diagRx
Aranesp 100 micrograms
Disp: 1
nosis (or ICD-9 diagnosis
Give injection SC in clinic Q2 weeks
code) for each medication to
Indication: CKD Stage IV (585.4),
be administered.
Anemia of Chronic Disease (285.21)
− This is similar to requirements for lab and radiology
Refills: 1
orders.
Signature
− Medications will not be
filled by pharmacy unless
Diagnosis Provided
Result
Potential Reimbursement
the appropriate diagnosis
585.4 CKD, Stage 4
Claim Accepted
and/or ICD-9 code is present
$300.00
285.21 Anemia in CKD
Payment received for Aranesp®
on the order.
−
The updated policy can be
285.9 Anemia, unspecified
Claim Rejected
$0
found on the MUSC Intranet
Applicable ICD-9 codes are needed for billing to receive reimbursement.
at the link below.

A.Doctoro

http://www.musc.edu/medcenter/policy/Med/C078.pdf
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Ensuring proper documentation of medication codes, administration codes, diagnosis codes and prior authorization when necessary increases the chance that the hospital will receive proper reimbursement for the services
that we offer and will improve the hospital’s “bottom line.”
Drug Codes + Administration Codes + Diagnosis Codes (± Prior Authorization) = REIMBUR$EMENT
It all makes economic CENT$

FORMULARY UPDATE FOR JUNE & JULY 2008
The Pharmacy and Therapeutics
Committee recently approved the
actions listed below.
®

Added: Callogenase (Santyl )
Collagenase is a selective debriding agent that is used in wound
care/debridement. Papain-urea
(Accuzyme®) is another commonly used agent used for wound
care and healing. Both agents
have been proven safe and effective. However, the Centers for
Medicare and Medicaid Services
will not reimburse for Accuzyme®. Therefore, the Committee voted to ADD Santyl® to the
formulary for wound care debridement. Accuzyme® will be removed.
15-, 30-gram tubes

Fenofibrate (TriCor®)
Fibric acid derivatives (eg, fenofibrate, gemfibrozil) maintain a role
in treating hypertriglyceridemia,
mixed dyslipidemia and/or impaired glucose homeostasis, and
isolated low levels of HDL-C.
Studies have shown that fenofibrate significantly reduces plasma
cholesterol and triglycerides over
placebo, and produces similar effects to gemfibrozil. Gemfibrozil
has shown greater reduction of
clinical events. However, gemfibrozil has multiple drug interactions, especially with concomitant
HMG CoA reductase inhibitor
(statin) use, and potentially higher

rates of muscle toxicities. Fenofibrate lacks significant effects
on statin metabolism, which is a
distinct advantage over gemfibrozil.
Although gemfibrozil
remains the more cost-effective
fibrate and has more studies for
reduction in clinical endpoints
and long-term safety, it may not
be tolerated by all patients due to
its significant drug interactions.
48-, 145-mg tablets

Restriction Added (Children’s
Hospital Only): Ergocalciferol
will now be restricted to use by
Neonatology and Pediatric Endocrinology. If ergocalciferol is
not ordered by Neonatology, Pediatric Endocrinology must be
contacted by the pharmacist to
review the order and approve its
use pertaining to the order. A
verbal order is acceptable. Approval from Pediatric Endocrinology must be documented in
eMeds. Additionally, all orders
for “vitamin D” must be clarified
for adult and pediatric patients.
Line Extensions:
▪ Ferrous gluconate [324-mg tablets]
▪ Cosyntropin [0.25 mg/mL injection]
▪ Aripiprazole (Abilify®) [7.5-mg/mL

▪
▪
▪
▪
▪
▪
▪
▪
▪
▪
▪
▪
▪
▪
▪
▪
▪
▪
▪
▪
▪
▪
▪

intramuscular injection]

▪ Tetracaine lollipops

▪

[extemporaneous]

Deletions:
▪ 95% sterile alcohol
▪ Amikacin 25-mg/0.5-mL

▪

subconjunctival injection
Amikacin 250-microgram/0.1-mL
intravitreal injection
Amphotericin 5 microgram/0.1-mL
ophthalmic injection
Aztreonam 20-mg/mL dilution
Bupivacine 0.75% with epinephrine
1:200,000 (Sensorcaine-MPF®)
30-mL vial
Cefotetan 200-mg/mL, 5-mL vial
Clindamycin 300-mg vial
Dextrose 30%, 1000-mL bag
Dianeal low calcium 4.2% dextrose
Dianeal 1.5% dextrose
Fluorescein 25%, 2-mL
Ibuprofen [400– and 600-mg tablets]
200– and 800-mg tablets still available
Inamrinone lactate 5-mg/mL injection
Nedocromil (Tilade®) inhaler
Ferumoxides 11.2 mg injection,
5-mL vial
Ganciclovir 200 micrograms/0.1-mL
intravitreal injection
Gentamicin 30 mg/mL, 10-mL
(buffered at pH 6.55)
Histamine (Histatrol) 0.275 mg/mL,
5-mL vial
Lidocaine 1.5%, 20-mL ampule
Procaine hydrochloride 2%, 10-mL
vial
Quinidine gluconate 80 mg/mL,
10-mL vial
Sodium phenylacetate 10%/sodium
benzoate 10% (Ammonul®) 5-g/50-mL
Sodium chloride 5%, 500-mL bag
Ammonium chloride 5 mEq/mL,
20-mL vials
Didanosine (Videx) 25-, 50-, 100-,
150-, 200-mg chewable tablets
Ferrous gluconate 300-mg tablets

